History
A list of downloadable documents created during development.
Background information
Macular degeneration (age-related) - pegaptanib and ranibizumab: Novartis Ranibizumab TA155
Macular degeneration (age-related) - pegaptanib and ranibizumab: DSU Ranibizumab TA155
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal panel decision
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement information
-
Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Derbyshire County PCT
-
-
-
Derbyshire County PCT: response to scrutiny letter (PDF 211 KB)
-
-
Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Pfizer
-
-
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: notice of appeal
Macular degeneration (age-related)- pegaptanib and ranibizumab: final appraisal determination
-
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
-
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Consultee and commentator comments on the ACD
-
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (confidential information removed)
-
-
-
-
Appendix 1 - Dose capping scheme summary proposal to NICE (PDF 21 KB)
-
-
Consultee and commentator comments on the ACD: Welsh Assembly Government (PDF 32 KB)
-
Consultee and commentator comments on the ACD: NHS Quality Improvement Scotland (PDF 24 KB)
-
Consultee and commentator comments on the ACD: Derbyshire County Primary Care Trust (PDF 28 KB)
-
-
Consultee and commentator comments on the ACD: Department of Health (PDF 34 KB)
-
-
Consultee and commentator comments on the ACD: Royal College of Ophthalmologists (PDF 29 KB)
-
Consultee and commentator comments on the ACD: Royal College of Nursing (PDF 25 KB)
-
Consultee and commentator comments on the ACD: Pfizer Limited (PDF 91 KB)
-
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (PDF 542 KB)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Expert comments on the ACD
-
-
-
Expert comments on the ACD: Professor Andrew Lotery (PDF 28 KB)
-
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 2 (December 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 2 (December 2007)
-
-
Evaluation report (December 2007)
-
Further analysis requested by NICE in response to consultation on the ACD
-
-
-
-
Consultee and Commentator comments on the further analysis requested by NICE in response to consultation on the ACD
-
Consultee and Commentator comments: External Experts
-
-
-
-
Consultee and Commentator comments: Other Consultees
-
-
-
Consultee and Commentator comments: Professional and Patient Groups
-
Macular Disease Society and Royal National Institute for the Blind (PDF 52 KB)
-
-
-
-
Consultee and Commentator comments: Manufacturer/Sponsor
-
-
-
First Appraisal Consultation document as issued to consultees
-
First Appraisal Consultation document (as issued to consultees) (PDF 112 KB)
-
Consultee and commentator comments on the first Appraisal Consultation
-
Consultee and commentator comments on the first Appraisal Consultation: External experts
-
-
-
-
-
-
Consultee and commentator comments on the first Appraisal Consultation: Commentators
-
-
Department of Health, Social Services and Public Safety for Northern Ireland (PDF 31 KB)
-
Consultee and commentator comments on the first Appraisal Consultation: Other Consultees
-
-
-
-
Consultee and commentator comments on the first Appraisal Consultation: Professional and patient groups
-
Royal National Institute of the Blind and Macular Disease Society (PDF 78 KB)
-
-
-
-
-
Royal College of Ophthalmologists - Covering letter (PDF 62 KB)
-
-
-
-
-
Consultee and commentator comments on the first Appraisal Consultation: Manufacturer / Sponsor
-
-
-
-
Report to the Appraisal Committee summarising patient and public comments on the first Appraisal consultation
-
Report summarising patient and public comments - Appendix 4 (PDF 6.37 MB)
-
Report summarising patient and public comments - Appendix 2 (PDF 280 KB)
-
Report summarising patient and public comments - Appendix 1 (PDF 1.08 MB)
-
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation document (Audio version) (December 2007)
-
-
-
-
-
-
-
-
-
-
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 1 (June 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 1 (June 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation information
-
Evaluation report
-
-
Macular degeneration (age-related) - ranibizumab and pegaptanib: assessment report (PDF 1.87 MB)
-
Consultee and commentator comments on the assessment report
-
-
-
-
-
-
Royal Institute for the Blind and Macular Disease Society (PDF 32 KB)
-
Non-manufacturer submission
-
-
-
-
Manufacturer submissions (executive summary only)
-
-
-
Expert written personal statements
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-